Theriva Biologics Inc (TOVX)

[Bornagain777]

"persisted in favor of the Trimesta" Does this mean that 47% was continuous after 24 months of treatment and that plus Copaxone placebo reduction in relapse was 32%. If so, where did we miss the end point.

women receiving Trimesta plus Copaxone demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment as compared to women receiving placebo plus Copaxone. In addition, a significant improvement in cognitive function was observed at 12 months as measured by Paced Auditory Serial Addition Test (PASAT) scores. After 24 months of treatment, the reduction in relapse rate persisted in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32 percent). Both treatment groups exhibited improvement in measures of cognitive.